Patent ID: 6953797

Claim:
A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I), wherein: X and Y independently represent C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CF 3 , OCF 3 , CN, C≡H, S(O) m CH 3 , S(O) p CF 3 , NO 2 or NHCHO; m and p independently represent an integer 0, 1 or 2; Z represents H or fluoro; V represents S(O) n or NR 3 ; W represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO 2 or NR 4 R 5 ; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms; R 1 and R 2 independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR 6 R 7 , phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF 3 , OCF 3 , CN or NO 2 ; or the group NR 1 R 2 together represents a 4 to 8 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S or NR 8 ; said ring being optionally substituted by C1 to 4 alkyl, C1 to 4 alkoxy or OH; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH or NR 9 R 10 ; R 3 represents H or C1 to 4 alkyl; R 4 , R 5 R 6 , R 7 , R 9 and R 10 independently represent H or C1 to 4 alkyl; R 8 represents H or C1 to 6 alkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH, NR 11 R 12 , phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF 3 , OCF 3 , CN or NO 2 ; R 11 and R 12 independently represent H or C1 to 4 alkyl; n represents an integer 0, 1 or 2; or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the inflammatory disease is selected from the group consisting of inilammatory bowel disease, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease and pain.